Literature DB >> 27370797

Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Warner Alpízar-Alpízar1,2,3, Ole Didrik Laerum1,2,4,5, Ib J Christensen1,2, Kjell Ovrebo6,7, Arne Skarstein8,7, Gunilla Høyer-Hansen1,2, Michael Ploug1,2, Martin Illemann1,2.   

Abstract

The tissue inhibitor of metalloproteinase-1 (TIMP-1) inhibits the extracellular matrix-degrading activity of several matrix metalloproteinases, thereby regulating cancer cell invasion and metastasis. Studies describing the expression pattern and cellular localization of TIMP-1 in gastric cancer are, however, highly discordant. We addressed these inconsistencies by performing immunohistochemistry and in situ hybridization analyses in a set of 49 gastric cancer lesions to reexamine the TIMP-1 localization. In addition, we correlated these findings to clinicopathological parameters. We show that strong expression of TIMP-1 protein and mRNA was observed in a subpopulation of stromal fibroblast-like cells at the periphery of the cancer lesions. In a few cases, a small fraction of cancer cells showed weak expression of TIMP-1 protein and mRNA. The stromal TIMP-1-expressing cells were mainly tumor-associated myofibroblasts. In the normal-appearing mucosa, scattered TIMP-1 protein was only found in chromogranin A positive cells. TIMP-1-positive myofibroblasts at the invasive front of the tumors were more frequently seen in intestinal than in diffuse histological subtype cases (p=0.009). A significant trend to a higher number of cases showing TIMP-1 staining in myofibroblasts with increasing tumor, node, metastasis (TNM) stage was also revealed (p=0.041). In conclusion, tumor-associated myofibroblasts are the main source of increased TIMP-1 expression in gastric cancer.
© 2016 The Histochemical Society.

Entities:  

Keywords:  TIMP-1; gastric cancer; immunohistochemistry; in situ hybridization; invasion; myofibroblasts; neuroendocrine cells

Mesh:

Substances:

Year:  2016        PMID: 27370797      PMCID: PMC4971780          DOI: 10.1369/0022155416656173

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  51 in total

Review 1.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.

Authors:  Mie Grunnet; Morten Mau-Sørensen; Nils Brünner
Journal:  Scand J Gastroenterol       Date:  2013-07-08       Impact factor: 2.423

2.  Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Authors:  Yixuan Gong; Uma D Chippada-Venkata; Matthew D Galsky; Jiaoti Huang; William K Oh
Journal:  Prostate       Date:  2015-01-05       Impact factor: 4.104

Review 3.  Pathology and molecular biology of gastric cancer.

Authors:  Matti Vauhkonen; Hanna Vauhkonen; Pentti Sipponen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

4.  Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma.

Authors:  M Mori; K Mimori; N Sadanaga; H Inoue; Y Tanaka; K Mafune; H Ueo; G F Barnard
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

5.  Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.

Authors:  Julie Lecomte; Anne Masset; Silvia Blacher; Ludovic Maertens; André Gothot; Marie Delgaudine; Françoise Bruyère; Oriane Carnet; Jenny Paupert; Martin Illemann; Jean-Michel Foidart; Ida K Lund; Gunilla Høyer-Hansen; Agnes Noel
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

6.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

7.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Pituitary Adenomas: Possible Markers of Neuroendocrine Cells.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

8.  Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Authors:  Martin Illemann; Nigel Bird; Ali Majeed; Ole D Laerum; Leif R Lund; Keld Danø; Boye Schnack Nielsen
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

9.  The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study.

Authors:  Hans Christian Rolff; Ib Jarle Christensen; Ben Vainer; Lars Bo Svendsen; Rikke Løvendahl Eefsen; Michael Wilhelmsen; Ida Katrine Lund; Gunilla Høyer-Hansen; Hans Jørgen Nielsen; Martin Illemann
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531

10.  Overexpression of tissue inhibitors of metalloproteinase-1 and -2 in the stroma of gastric cancer.

Authors:  S I Hong; I C Park; W S Hong; Y S Son; S H Lee; J I Lee; D W Choi; N M Moon; T B Choe; J J Jang
Journal:  J Korean Med Sci       Date:  1996-12       Impact factor: 2.153

View more
  7 in total

Review 1.  The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Authors:  Ruth M Escalona; Emily Chan; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

2.  Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis.

Authors:  Xinkui Liu; Jiarui Wu; Dan Zhang; Zhitong Bing; Jinhui Tian; Mengwei Ni; Xiaomeng Zhang; Ziqi Meng; Shuyu Liu
Journal:  Front Genet       Date:  2018-07-17       Impact factor: 4.599

3.  Total saponins from Lilium lancifolium: a promising alternative to inhibit the growth of gastric carcinoma cells.

Authors:  Yin-Yu Zhang; Lin-Ming Luo; Yu-Xiang Wang; Neng Zhu; Tan-Jun Zhao; Li Qin
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

4.  Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes.

Authors:  Aitor Rodríguez-Martínez; Carla Trapero; August Vidal; Josep Maria Piulats; Inmaculada Gómez de Aranda; Jean Sévigny; Maria Eulàlia Fernández-Montolí; Jordi Ponce; Xavier Matias-Guiu; Mireia Martín-Satué
Journal:  J Pers Med       Date:  2021-04-22

5.  Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.

Authors:  Olga Prokopchuk; Barbara Grünwald; Ulrich Nitsche; Carsten Jäger; Oleksii L Prokopchuk; Elaine C Schubert; Helmut Friess; Marc E Martignoni; Achim Krüger
Journal:  BMC Cancer       Date:  2018-02-02       Impact factor: 4.430

6.  Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis.

Authors:  Anastasia Chillà; Francesca Margheri; Alessio Biagioni; Mario Del Rosso; Gabriella Fibbi; Anna Laurenzana
Journal:  J Exp Clin Cancer Res       Date:  2018-04-03

7.  A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis.

Authors:  Renata Binato; Everton Cruz Santos; Mariana Boroni; Samia Demachki; Paulo Assumpção; Eliana Abdelhay
Journal:  Oncotarget       Date:  2017-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.